Geron Market Capitalization from 2010 to 2025

GERN Stock  USD 1.76  0.02  1.15%   
Geron Market Cap yearly trend continues to be very stable with very little volatility. Market Cap is likely to grow to about 2.4 B this year.
Check Geron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Geron's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 19.4 M or Selling General Administrative of 153 M, as well as many indicators such as Price To Sales Ratio of 28.22, Dividend Yield of 0.0 or PTB Ratio of 8.57. Geron financial statements analysis is a perfect complement when working with Geron Valuation or Volatility modules.
  
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.

Latest Geron's Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Geron over the last few years. It is Geron's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Geron's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 1.12 B10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

Geron Market Capitalization Regression Statistics

Arithmetic Mean684,297,672
Geometric Mean445,392,453
Coefficient Of Variation104.15
Mean Deviation519,653,884
Median431,621,821
Standard Deviation712,724,655
Sample Variance507976.4T
Range2.3B
R-Value0.74
Mean Square Error247999.1T
R-Squared0.54
Significance0
Slope110,449,064
Total Sum of Squares7619646.5T

Geron Market Capitalization History

20252.4 B
20242.3 B
20231.2 B
2022921.5 M
2021399.7 M
2020431.6 M

About Geron Financial Statements

Geron investors utilize fundamental indicators, such as Market Capitalization, to predict how Geron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock:
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.27)
Revenue Per Share
0.119
Quarterly Revenue Growth
2.1 K
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.